PARTIAL THROMBOPLASTIN TIME

Presented by: Alexandra Regilyne M. Romero Janela Cruz Nica Rayo Paul De Luna

PARTIAL THROMBOPLASTIN TIME

Also called as the Activated Partial Thromboplastin Time or APTT
It is performed to monitor the effects of unfractionated heparin therapy and to detect LA and specific anticoagulation factor antibodies such as anti-factor VIII antibody.

PROCEDURE
Specimen: Citrated plasma Reagent used: PTT reagent
Composition of reagent: phospholipid (previously called partial thromboplastin) Negatively charged particulate activator (silica, kaolin, ellagic acid, or celite in suspension) 0.025 mol/L calcium chloride

PROCEDURE
Warm a sufficient quantity of the PTT reagent to 37C Pipette 50 or 100 mcL of warmed reagent in a test tube mix it with an equal volume of warmed PPP. Incubate the mixture for the specified time set by the manufacturer (usually 3 minutes)

PROCEDURE
Forcefully add 50 or 100 mcL of warmed 0.025 mol/L calcium chloride to the mixture and start the timer immediately. Mix the tube once, immediately after adding the calcium reagent. Allow the tube to stand for a few seconds. Gently tilt the tube back and forth until a visible clot forms.

PROCEDURE
When a fibrin clot forms, stop the timer immediately and record the time in seconds. Repeat the procedure for a second run of control. Record the time and average the two results if they match appropriately (within 10%). If not, repeat a third time and average the two that match within acceptable limits

PTT TIME INTERVAL

The PTT reference interval varies from site to site depending on:
The patients population Type of reagent Type of instrument pH and purity of the diluent

NV: 26 to 38 seconds

CLINICAL APPLICATIONS
Unfractionated heparin monitoring (which is used during coronary artery bypass graft surgery, cardiac catheterization, and in several medical conditions.) Clotting factor deficiency or coagulation inhibitor detection

CLINICAL SIGNIFICANCE
PTT IS PROLONGED IN THE FOLLOWING CONDITIONS..
Coagulation factor deficiencies: X, VIII, IX, XI, XII, V, I, II Presence of interfering substance such as fibrin degradation products (FDPs) or paraproteins which are present in myeloma Vitamin K deficiency DIC Liver Disease

-ENDTHANK YOU!